Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4151
-0.00590-1.40%
At close: -
$0.4100
-0.00510-1.23%
After Hours: 7:04 PM EDT
Comments
Loading...
Equillium Analyst Ratings and Price Targets | NASDAQ:EQ | Benzinga
Equillium Inc has a consensus price target of $4.56 based on the ratings of 6 analysts. The high is $7 issued by Stifel on March 24, 2023. The low is $1 issued by Leerink Partners on March 28, 2025. The 3 most-recent analyst ratings were released by Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co. on March 28, 2025, August 19, 2024, and June 5, 2024, respectively. With an average price target of $3.67 between Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 794.31% upside for Equillium Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
HC Wainwright & Co.
Cantor Fitzgerald
Stifel
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Equillium
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
03/28/2025 | 143.9% | Leerink Partners | $3 → $1 | Downgrade | Outperform → Market Perform | |||
11/01/2024 | — | Jones Trading | — | Downgrade | Buy → Hold | |||
08/19/2024 | 1119.51% | HC Wainwright & Co. | $5 → $5 | Reiterates | Buy → Buy | |||
06/05/2024 | 1119.51% | HC Wainwright & Co. | $5 → $5 | Reiterates | Buy → Buy | |||
05/17/2024 | 1119.51% | HC Wainwright & Co. | $5 → $5 | Reiterates | Buy → Buy | |||
04/02/2024 | 1119.51% | HC Wainwright & Co. | $4 → $5 | Maintains | Buy | |||
12/26/2023 | 875.61% | HC Wainwright & Co. | $4.5 → $4 | Maintains | Buy | |||
11/13/2023 | 997.56% | HC Wainwright & Co. | $5.5 → $4.5 | Maintains | Buy | |||
08/14/2023 | 582.93% | Cantor Fitzgerald | → $2.8 | Reiterates | Overweight → Overweight | |||
08/14/2023 | 1241.46% | HC Wainwright & Co. | → $5.5 | Reiterates | Buy → Buy | |||
05/15/2023 | 1241.46% | HC Wainwright & Co. | → $5.5 | Reiterates | Buy → Buy | |||
05/01/2023 | 1241.46% | HC Wainwright & Co. | $20 → $5.5 | Maintains | Buy | |||
03/24/2023 | 1607.32% | Stifel | $12 → $7 | Maintains | Buy | |||
02/08/2023 | 1607.32% | SVB Leerink | $12 → $7 | Maintains | Outperform | |||
09/27/2022 | 4778.05% | HC Wainwright & Co. | $15 → $20 | Maintains | Buy | |||
09/08/2022 | 2826.83% | SVB Leerink | $14 → $12 | Maintains | Outperform |
FAQ
What is the target price for Equillium (EQ) stock?
The latest price target for Equillium (NASDAQ:EQ) was reported by Leerink Partners on March 28, 2025. The analyst firm set a price target for $1.00 expecting EQ to rise to within 12 months (a possible 143.90% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Equillium (EQ)?
The latest analyst rating for Equillium (NASDAQ:EQ) was provided by Leerink Partners, and Equillium downgraded their market perform rating.
When was the last upgrade for Equillium (EQ)?
There is no last upgrade for Equillium
When was the last downgrade for Equillium (EQ)?
The last downgrade for Equillium Inc happened on March 28, 2025 when Leerink Partners changed their price target from $3 to $1 for Equillium Inc.
When is the next analyst rating going to be posted or updated for Equillium (EQ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Equillium, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Equillium was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Equillium (EQ) correct?
While ratings are subjective and will change, the latest Equillium (EQ) rating was a downgraded with a price target of $3.00 to $1.00. The current price Equillium (EQ) is trading at is $0.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
